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Background: Transcatheter arterial chemoembolisation (TACE) is the treatment of choice for intermediate stage hepatocellular
carcinoma (HCC). Doxorubicin-loaded drug-eluting beads (DEB)-TACE is expected to improve the performance of conventional
TACE (cTACE). The aim of this study was to compare DEB-TACE with cTACE in terms of time-to-tumour progression (TTP),
adverse events (AEs), and 2-year survival.
Methods: Patients were randomised one-to-one to undergo cTACE or DEB-TACE and followed-up for at least 2 years or until
death. Transcatheter arterial chemoembolisation was repeated ‘on-demand’.
Results:We enrolled 177 patients: 89 underwent DEB-TACE and 88 cTACE. The median number of procedures was 2 in each arm,
and the in-hospital stay was 3 and 4 days, respectively (P¼ 0.323). No differences were found in local and overall tumour response.
The median TTP was 9 months in both arms. The AE incidence and severity did not differ between the arms, except for post-
procedural pain, more frequent and severe after cTACE (Po0.001). The 1- and 2-year survival rates were 86.2% and 56.8% after
DEB-TACE and 83.5% and 55.4% after cTACE (P¼ 0.949). Eastern Cooperative Oncology Group (ECOG), serum albumin, and
tumour number independently predicted survival (Po0.05).
Conclusions: The DEB-TACE and the cTACE are equally effective and safe, with the only advantage of DEB-TACE being less post-
procedural abdominal pain.
Worldwide, hepatocellular carcinoma (HCC) is the fifth most
common cancer in men and the sixth in women, representing the
third leading cause of tumour-related death (El-Serag, 2012).
The majority of HCCs are associated with liver cirrhosis, and the
prognosis is so poor that mortality and incidence are fairly similar
(El-Serag, 2012).
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According to Barcelona Clinic Liver Cancer (BCLC) tumour
staging and management (Bruix and Llovet, 2002), endorsed by the
American (AASLD) and European (EASL-EORTC) guidelines for
HCC management (Bruix and Sherman, 2005; Llovet et al, 2012),
transcatheter arterial chemoembolisation (TACE) is recommended
as first-line therapy for unresectable intermediate-stage HCC
(stage B). This evidence-based position reflects the results of three
studies showing that TACE significantly improves patient survival
as compared with best supportive care (Llovet et al, 2002; Lo et al,
2002; Llovet and Bruix, 2003). Despite the widespread use of
screening programmes, 60–70% of HCCs are detected when
curative treatments (surgery or ablation) are precluded by the
cancer burden or contraindications (Bruix and Llovet, 2002;
Takayasu et al, 2012). In fact, TACE is the most common
treatment modality used in HCC patients, and almost half of
TACEs are carried out for early tumours unsuitable for curative
treatment (Varela et al, 2010).
Agreement regarding the best TACE technique has not yet been
reached, and various options concerning patient selection, delivery
systems, selectivity of treatment, drugs and embolic agents injected,
and repetition schedules (predefined vs ‘on demand’) are still in use
(Marelli et al, 2007), making the results reported in the literature
very inhomogeneous.
Transcatheter arterial chemoembolisation with calibrated dox-
orubicin-carrying microspheres, DC-Beads (DEB-TACE), have
been introduced as a novel device capable of ensuring more
sustained and tumour-selective drug delivery and permanent
embolisation (Varela et al, 2007), which could satisfy the
requirement for standardising treatment regimens. A multicentre
international randomised trial (Lammer et al, 2010) comparing the
short-term outcomes of DEB-TACE and conventional TACE
(cTACE) in terms of toxicity and radiologic tumour response
indicated some advantages of the first technique, particularly in
‘fragile’ subgroups, such as Child-Pugh B and performance status
(PS) 40 patients, and in those with bilobar or recurrent tumours.
Despite these appealing premises, the superiority of DEB-TACE
over cTACE in terms of patient survival has yet to be
demonstrated. Two retrospective studies (Dhanasekaran et al,
2010; Song et al, 2012), affected by several biases, have
suggested the superiority of DEB-TACE whereas a small
randomised controlled trial has not confirmed this superiority
(Sacco et al, 2011).
To elucidate this key point, we conducted a prospective,
multicentre randomised controlled study involving a large series
of cirrhotic patients with HCC not amenable to curative therapy.
The aim was to compare the 2-year survival achievable with DEB-
TACE and cTACE in homogeneous patients.
MATERIALS AND METHODS
Study population. Patients 418 years of age, with HCC
unsuitable for curative treatment or had failed/recurred after
resection/ablation and diagnosed by biopsy or according to the
AASLD criteria (Bruix and Sherman, 2005), were eligible for the
study. Causes of non-qualification for curative treatments were
contraindications to liver transplant; poor liver function (Child-
Pugh class B or MELD score 410), severe comorbidities and
patient refusal for resection; critical location or non-visibility at
ultrasonography of nodules and not permissive clotting/platelet
count for ablation. The inclusion criteria were patients belonging
to class Child-Pugh A or B (score 7) and with an Eastern
Cooperative Oncology Group (ECOG) PS p1, no previous
treatment on target lesions (prior treatments on non-target lesions
were accepted). The exclusion criteria were infiltrative HCC, portal
vein thrombosis, ascites, F3 oesophageal varices, advanced liver
disease (bilirubin levels X2.5mg dl 1, albumin p30 g l 1, plate-
letsp50 109 per litre, INR41.5), other tumours in the previous
5 years, and contraindications to arteriography or TACE. Previous
locoregional treatment (including resection) of non-target lesions
did not preclude enrolment.
All patients provided written informed consent. This study was
conducted in accordance with the Good Clinical Practice principles
and the Declaration of Helsinki. Independent Data and Safety
Monitoring Committees were established to monitor efficacy and
safety data. Ethics committee approval was obtained. The study
was registered at www.clinicaltrials.gov (NCT00936689).
Study design. The study, called ‘Precision Italia’, was a multi-
centre, prospective, randomised, open-label, active-controlled
study in which patients were randomised one-to-one to undergo
cTACE or DEB-TACE. The study required a post-TACE follow-up
for at least 2 years or until death. Upon enrolment, alphanumeric
identification codes were assigned to the patients who were then
randomised to one of the two treatments. The randomisation was
stratified according to Child-Pugh class and BCLC stage and it was
centralised at the Investigational Drug Service of the Pharmacy of
the Bologna center, allocating the first and lowest randomisation
code available, and generating the randomisation list.
Patients underwent TACE as follows: (1) patients of the
cTACE group (Arm A) received a mixture of dry epirubicin
(Farmorubicin; Pfizer, Latina, Italy) manually emulsified with
iodised oil (Lipiodol; Guerbet, Milan, Italy) in a proportion of 1 to
1 vial (50mg of drug with 10ml of Lipiodol) to a maximum
administered dose of 75mg, followed by embolisation with
absorbable gelatin sponge particles (Gelita-Spon; Gelita Medical,
Amsterdam, The Netherlands); (2) patients of the DEB-TACE
group (Arm B) received DC-Beads (Biocompatibles, Farnham,
Surrey, UK), 100–300 mm in diameter (each vial was loaded with
50mg of a doxorubicin solution; Pfizer) mixed with non-ionic
contrast medium. In both arms, chemoembolisation was performed
as selectively as possible (segmental (selective) or subsegmental
(superselective)) using a 2.7–2.8 French microcatheter.
In the cTACE group, the mixture was injected until saturation
of the tumour feeding arteries, and the subsequent embolisation
end point was to reduce the residual blood flow. In the DEB-TACE
group, we injected the loaded microspheres until full saturation of
the tumour feeding arteries, without injection of other embolic
agents.
Transcatheter arterial chemoembolisation was repeated ‘on
demand’ upon demonstration of a persistent viable tumour (i.e.,
the absence of complete response (CR)) or intra-hepatic distal
recurrence at imaging follow-up, provided that liver function had
not deteriorated (Child-Pugh score 47).
Efficacy evaluation. The response was evaluated by Multidetector
Computer Tomography (MDCT) or Magnetic Resonance Imaging
(MRI) as local (per-lesion) tumour response and overall (per-
patient) response, according to the EASL criteria (until 2010) and,
subsequently, to the modified RECIST (mRECIST) (Lencioni and
Llovet, 2010), at 1 month after each TACE and, thereafter, every
3 months, for at least 2 years. An objective response (OR) was
defined as CR plus partial response (PR), while disease control (DC)
was defined as OR plus stable disease (SD).
Study aims and hypothesis. The primary aim of the study was to
compare 2-year survival between the two study arms. The
secondary end points were radiological tumour response, time-
to-tumour progression (TTP: interval between randomisation and
radiological tumour progression), impact on PS and liver function,
number of treatments, duration of in-hospital stay and need for
other types of treatment of residual/recurrent tumours. For
obvious ethical reasons and since our investigation aimed at
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achieving results similar to those achievable with the HCC
therapies usually adopted in our country (pragmatic trial), the
study design allowed referral physicians to treat tumour persis-
tence/progression after at least two TACEs with alternative
treatments (ablation, surgery or sorafenib administration). Accord-
ing to the rules of the Italian Drug Regulatory Agency (AIFA),
sorafenib was dispensed to patients who were in Child-Pugh class
A at the time of tumour progression.
Safety evaluation. Adverse events (AEs) and serious adverse
events (SAEs) were monitored and recorded. Adverse events were
assessed during and after each treatment, and at all follow-up visits
and graded according to the NCI Common Terminology Criteria
for Adverse Events (CTCAE) version 3.0. The AEs occurring
within 4 weeks after TACE were considered as treatment related;
whenever they occurred after 4 weeks, they were reported only if a
causal correlation was suspected.
Statistical analysis. The study was designed to demonstrate the
superiority of DEB-TACE over cTACE in 2-year survival,
assuming a 40% survival rate in the cTACE arm and a 20%
improvement in the DEB-TACE arm. To detect this difference,
with 80% power and a 5% significance level, we calculated that 214
patients, 107 per treatment arm, had to be enrolled (Fleiss, 1973).
Two formal interim analyses, planned after B50% and 75% of
enrolment, were conducted by an external statistician to assess
survival at 24 months post treatment. The first interim analysis,
involving 116 patients (57 cTACE and 59 DEB-TACE cases; 54%
of the planned sample size), showed no difference between the two
arms (Mantel–Haenszel, P¼ 0.853). Similarly, the second interim
analysis, involving 177 patients (88 cTACE and 89 DEB-TACE),
showed no difference between arms (Mantel–Haenszel, P¼ 0.949).
A reviewer committee, formed by two experts external to the study,
and an external statistician, was thus consulted on the utility of
continuing enrolment. Since it was highly unlikely that extended
enrolment would reveal the superiority of DEB-TACE, the
committee recommended stopping the trial for futility (Pocock,
1992). The results presented here are therefore derived from a
population of 177 patients, representing 83% of the original
planned sample size (Figure 1).
Survival and safety analyses included all randomised patients
who underwent at least one TACE (intention-to-treat analysis).
The Kaplan–Meier method was used to calculate survival curves,
and the Mantel–Haenszel test was used for treatment comparisons.
For patients who became transplantable after a downstaging
programme, survival was censored at the day before surgery.
Categorical variables are reported in numbers and percentages.
The variable distribution was checked with the Kolmogorov–
Smirnov test, and the values are reported as mean±standard
deviation, or median and range, as appropriate. Comparisons
between groups were carried out using the Fisher’s exact test,
ANOVA, or Mann–Whitney. In addition to P-values, which are
affected by sample size, effect sizes (or standardised differences)
were computed: values o0.1 indicated very small differences, 0.1–
0.3 small differences, 0.3–0.5 moderate differences, and40.5 large
differences (Burnand et al, 1990).
Univariate and multivariate Cox proportional hazard analyses
were used to assess the prognostic role of baseline patient
characteristics. Variables associated (Po0.10) with overall survival
at univariate analysis were entered into the multivariate regression
model. The regression model was further explored by including the
‘primary exposure variable’ (TACE treatment) even if it had
a P-value of 40.10 at univariate analysis. A two-tailed P-value of
o0.05 was considered as statistically significant. Statistical
evaluations were carried out using the SPSS version 13.0 for
Windows (IBM, Armonk, NY, USA).
RESULTS
Patients were enrolled between March 2008 and December 2010;
the date of the last follow-up evaluation was December 2012. The
flow chart of the study is summarised in Figure 1. Fifty-eight
(32.7%) randomised patients had undergone previous treatments,
31 in the cTACE group (40 treatments in all: 15 cTACE, 16
percutaneous treatments, and 9 resections) and 27 in the DEB-
TACE group (37 treatments in all: 9 cTACE, 21 percutaneous
treatments, and 7 resections) (P¼ 0.524). In all, 36 (20%) patients
received subsequent treatments that were equally distributed in the
two arms (P¼ 0.404): liver transplant in 6 cTACE and 4 DEB-
TACE patients, sorafenib in 14 cTACE and 9 DEB-TACE cases,
ablative procedures in 1 cTACE and 1 DEB-TACE patient, and
resection in 1 DEB-TACE subject.
During the 2-year follow-up after TACE, 73 (41.2%) patients
died, 36 (40.9%) in the cTACE arm, and 37 (41.6%) in the
Patients assessed for eligibility:
n =184  
Patients excluded (n =7): 
- Not meeting inclusion criteria: n =5 
-  Declined to participate: n =2 
Drop-out (n =2):
 
- Protocol violation: n =1
- Withdrew consent: n =1
Assigned to cTACE: n =88
 
Received allocated intervention: n =88 
Assigned to DEB-TACE: n =89
Received allocated intervention: n =89 
Patients randomised: n =177
Complete follow-up: n =86
Drop-out (n =1):
- Protocol violation: n =1
Complete follow-up: n =88
Figure 1. Summary flow chart of the study.
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DEB-TACE arm. The causes of death were sepsis in 1 patient
(1.4%), tumour progression in 49 (67.1%), liver failure in 17
(23.3%), and other causes in 6 (8.2%).
Baseline patient characteristics are reported in Table 1. No
significant differences were observed in clinical and tumoural
characteristics between the two groups. All the 46 patients
classified as BCLC C were allocated to this stage due to ECOG-1.
Patients in the cTACE arm received 47.2±14.6mg of epirubicin
and 10.3±3.8ml of Lipiodol whereas patients in the DEB-TACE
arm received 57.8±24.1mg of doxorubicin. Two-thirds of the
patients in each arm underwent segmental TACE treatment.
After the 30-day follow-up visit, 21 (24.1%) cTACE and 28
(31.5%) DEB-TACE patients repeated the procedure (P¼ 0.315).
At the 3-month assessment, 15 (18.8%) cTACE and 13 (17.3%)
DEB-TACE patients were re-treated (P¼ 0.838). A similar
re-treatment rate between the groups was maintained also at the
6-month (P¼ 0.376) and the 9-month assessments (P40.999).
As a result, the median number of treatments was 2 in both the
cTACE (range: 1–4) and the DEB-TACE arms (range: 1–5).
Tumour response. At 30 days, radiological evaluation of the
tumour response was available in all but one patient who had died
after the first cTACE from septic shock. A local CR (of the target
lesions) was observed in 101 patients (57.1%), overall CR in 91
(51.4%), PR in 66 (37.3%), SD in 6 (3.4%), and progressive disease
(PD) in 13 (7.3%). Thus, OR was obtained in 157 patients (88.7%)
and DC in 163 (92.1%). No significant differences were found in
the rates of local (CR, OR, and DC) (Figure 2) and overall tumour
responses during the follow-up period (P40.05 in all cases), except
for a more frequent overall CR at 1 month after cTACE than after
DEB-TACE (59.8% vs 43.8%; P¼ 0.036) (Figure 3). Conversely, a
trend towards a higher rate of local CR after DEB-TACE was
observed at 6 months (68.7% vs 63.5%). This trend, however,
conflicted with a tendency to a higher rate of overall CR after
cTACE at the same time point (58.1% vs 52.2%), due to the lower
occurrence of new nodules in cTACE (5 out of 20, 25%) than in
DEB-TACE patients (9 out of 23, 39%) at the time of progression,
although this difference did not reach statistical significance
(P¼ 0.353).
We also conducted post hoc analyses on overall tumour response
in some patient subgroups (Table 2). At 30 days, an overall CR was
significantly more frequent after cTACE than after DEB-TACE in
ECOG-0 (P¼ 0.014) and BCLC class A (P¼ 0.027) patients.
TTP and survival. For all patients, the median TTP was 9 months
(95% CI: 7.3–10.7), namely 9 months (95% CI: 6.3–11.7) in the
cTACE arm and 9 months (95% CI: 6.8–11.2) in the DEB-TACE
arm (P¼ 0.766).
In the entire population, the 1- and 2-year survival rates were
84.8% and 56.2%, respectively. The corresponding figures were
83.5% and 55.4%, respectively after cTACE, and 86.2% and 56.8%
after DEB-TACE (P¼ 0.949) (Figure 4). Based on these figures, the
median survival projection was 29 months for all patients, 28
months for cTACE patients and 29 months for DEB-TACE
patients. A post hoc analysis on survival showed that the 1- and
2-year survival rates were 88.6% and 68.6% in BCLC A, 85.4% and
64.2% in BCLC B, and 77.5% and 50.1% in BLCL C patients (P for
trend¼ 0.033). Conversely, the 1- and 2-year survival rates were
not significantly affected by the ‘naı¨ve’ status, being 89.5% and
65.9% in naı¨ve cases against 75.4% and 55.6% in previously treated
individuals (P¼ 0.156).
Table 1. Baseline clinical and tumour characteristics of the study population randomised to receive cTACE or DEB-TACE
All patients (n¼177) cTACE (n¼88) DEB-TACE (n¼89) P Effect size
Clinical characteristics
Age (years) 68.6±8.0 68.3±8.0 68.9±8.0 0.556 0.075
Male gender 135 (76.3%) 69 (78.4%) 66 (74.2%) 0.597 0.079
Viral cirrhosis 130 (73.4%) 68 (76.4%) 62 (70.5%) 0.399 0.127
Alcohol consumption 36 (20.8%) 20 (22.7%) 16 (18.0%) 0.460 0.111
Child-Pugh class A 152 (85.9%) 77 (87.5%) 75 (84.3%) 0.667 0.065
Class B 25 (14.1%) 11 (12.5%) 14 (15.7%) — 0.065
ECOG score 0 131 (74.0%) 67 (75.3%) 64 (72.7%) 0.734 0.051
Score 1 46 (26.0%) 21 (24.3%) 25 (27.3%) — 0.051
Serum albumin (g l 1) 37.6±5.1 37.6±4.8 37.7±5.5 0.949 0.019
Creatinine (mgdl 1) 0.87±0.21 0.86±0.22 0.88±0.20 0.433 0.095
Total bilirubin (mgdl 1) 1.24±0.67 1.20±0.57 1.28±0.74 0.383 0.121
INR 1.22±0.16 1.22±0.18 1.21±0.13 0.575 0.064
MELD score 9.8±2.4 9.7±2.4 9.8±2.3 0.747 0.043
Segmental injection 122 (68.9%) 60 (68.2%) 62 (69.8%) 0.872 0.024
Tumour burden
Single tumour 84 (47.5%) 39 (44.3%) 45 (50.6%) 0.453 0.113
More than three tumours 21 (11.9%) 11 (12.5%) 10 (11.2%) 0.820 0.034
BCLC stage A 82 (46.3%) 41 (46.6%) 41 (46.1%) 0.876 0.010
Stage B 49 (27.7%) 23 (26.1%) 26 (29.2%) — 0.069
Stage C 46 (26.0%) 24 (27.3%) 22 (24.7%) — 0.089
Bilobar involvement 37 (20.9%) 20 (22.7%) 17 (19.1%) 0.584 0.082
Diameter of largest tumour (cm) 3.2±1.8 3.4±1.9 3.1±1.6 0.382 0.171
Median (range) 2.6 (0.9–10) 2.8 (1.0–10) 2.5 (0.9–9) 0.734 0.076
TTV cm3 (median, range) 11.5 (1.0–408) 12.8 (1.0–408) 10.8 (1.0–368) 0.412 0.011
Abbreviations: BCLC¼Barcelona Clinic Liver Cancer; cTACE¼ conventional transarterial chemoembolisation; DEB-TACE¼drug-eluting beads transarterial chemoembolisation; ECOG¼
Eastern Cooperative Oncology Group; INR¼ international normalized ratio; MELD¼model for end-stage liver disease; TTV¼ total tumour volume. Effect size o0.1 indicates very small
differences; between 0.1 and 0.3 indicates small differences, and 40.3 indicates moderate to large differences; for variables reported in median and range effect size derive from Log10
transformation. No patients belonging to Child-Pugh class C were included in this study.
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The type of TACE did not affect patient survival at the
univariate regression analysis whereas ECOG-1, low serum
albumin, and multiple tumours independently and adversely
conditioned survival (Table 3). When the multivariate model was
forced to include the TACE type, ECOG-1, serum albumin, and
multiple tumours were confirmed as independent prognostic
factors, and the treatment type remained insignificant (P¼ 0.410;
Hazard ratio: 0.821; 95% CI: 0.513–1.313) (Table 3).
Safety. Adverse events are reported in Table 4. There was no
significant difference in the incidence of all AEs except post-
procedural pain, which was two-fold more frequent and more
severe in the cTACE arm than in the counterpart. The SAEs were
rare in both arms (o7%). A significant worsening of liver function
at 1 month was exceptional (3.4%) and equally distributed between
the two arms.
In-hospital stay length. The median in-hospital stay was 4 days
(range: 1–26) for cTACE patients and 3 days (range: 1–34) for
DEB-TACE patients (P¼ 0.323).
DISCUSSION
Transcatheter arterial chemoembolisation is considered as the
standard treatment for patients with HCC in the BCLC
intermediate stage (Bruix and Llovet, 2002; Llovet et al, 2012)
but it is also used in early-stage HCC patients excluded from
potentially curative treatment. In fact, as in other studies (Varela
et al, 2010; Burrel et al, 2012; Takayasu et al, 2012), early HCC
patients represented a notable proportion of our cases. Conven-
tional TACE suffers from several technical problems, such as
lack of standardisation of the procedure and escape of the
chemotherapeutic agent from the treated portion of liver. These
limitations are theoretically reduced by DEB-TACE. The current
study is a head-to-head comparison of survival between DEB-
TACE and well-standardised cTACE which, until now, has only
been addressed by a small randomised study (Sacco et al, 2011).
Our study did not demonstrate any difference in local and
overall response and DC between cTACE and DEB-TACE, except
at 1 month when cTACE achieved a higher rate of overall CR. As
this superiority disappeared thereafter, when lipiodol staining
decreased, it probably represents a spurious benefit due to the
‘masking effect’ of lipiodol at the first post-TACE evaluation with
MDCT. This potential inaccuracy in the initial tumour response
was accepted at the time we designed the study for two reasons;
first, in clinical practice MDCT is more easily available than MR,
and is one of tools recommended to control TACE results (Bruix
and Sherman, 2005); second, the primary objective of the study was
to compare the survival of patient undergoing the two procedures.
The 3-month OR rate (about 74%), seen in both treatment arms,
is in line with what was reported in our previous study (Golfieri
et al, 2013) using cTACE, and by Song et al (2012) with DEB-
TACE. In the Korean series, the OR achieved with cTACE was
much lower (49.4%) than ours, possibly due to a defectively
standardised procedure. These authors also reported a better
response with DEB-TACE in intermediate-stage but not in early-
stage tumours, suggesting that this technique could facilitate
treatment of larger lesions. Such a stage-dependent difference in
the efficacy between the two types of TACE was not confirmed by
our study, which did not detect any differences in the CR rates
between treatment arms according to BCLC stage, lobar/bilobar
tumoural extension or Child-Pugh class.
Our results also conflict with the first multicentric randomised
European trial (Lammer et al, 2010), reporting a better response at
44.8
53.8
58.158.059.8
48.954.552.255.7
43.8
30%
40%
50%
60%
70%
1-month CR 3-month CR 6-month CR 9-month CR 12-month CR
P =0.036 P =0.873 P =0.502
P >0.999
P =0.698
51.7
61.5
70.374.1
88.5
55.358.259.7
74.7
89.9
40%
50%
60%
70%
80%
90%
100%
1-month OR 3-month OR 6-month OR 9-month OR 12-month OR
P =0.812
P >0.999
P =0.217
P =0.713 P =0.844
58.6
67.773.0
77.8
92.0
61.765.565.7
79.7
93.3
50%
60%
70%
80%
90%
100%
1-month DC 3-month DC 6-month DC 9-month DC 12-month DC
cTACE DC Beads
P =0.718
P =0.848
P =0.366
P =0.847
P =0.842
Figure 3. Overall response of the entire liver according to mRECIST
criteria. Abbreviations: CR¼ complete response; DC¼disease control;
OR¼objective response.
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CR¼ complete response; DC¼disease control; OR¼objective
response.
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6 months with DEB-TACE in more compromised patients (Child-
Pugh B, ECOG-1, bilobar, or recurrent disease). However, in this
trial the SAE incidence wasB20% in both cTACE and DEB-TACE
patients, leading to treatment discontinuation in 13% of cases. This
trial also reported significantly reduced side effects after DEB-
TACE. These figures are much higher than ours (6.2%), regardless
of the type of TACE we employed. Such different findings could be
related both to the TACE reiteration at 2-month intervals
regardless of tumour response (82% of patients received a second
TACE and B60% a third TACE), and to the high amount of
Doxorubicin (up to 150mg per course) utilised in the European study.
In this respect, it is important to note that we injected the
microspheres (as well as the mixture of epirubicin and Lipiodol)
through microcatheters (2.7–2.8 French) and until full saturation of
the tumour feeding arteries was obtained. This allowed us reaching
the maximal administrable dose in a superselective modality using the
smallest microspheres (100–300mm), and hence avoiding the risk of
under-treating target lesions, as indirectly confirmed by the high rate
of CR we obtained. Therefore, the higher drug dose utilised in the
European trial was probably due to a less selective approach and/or a
greater median size of the lesions allowing the injection of larger
spheres (300–700mm). Finally, a recent meta-analysis based on seven
studies (693 patients) demonstrated that the two procedures had
equivalent results, strongly supporting our findings regarding the lack
of difference in tumour response between the two procedures (Gao
et al, 2013).
As expected, in our study, moderate and severe periprocedural
pain was less frequent after DEB-TACE and a lower rate of liver
function impairment or SAEs was observed as compared with
previous studies (Malagari et al, 2008; Lammer et al, 2010),
probably due to the lower doses of anticancer drugs administered.
Systemic AEs, such as mucositis, alopecia, and bone marrow
toxicity, were not observed in either treatment group. This safe
systemic profile of cTACE could be attributed to the superselective
technique we used, allowing the infusion of relatively small doses
of anticancer agents to fully soak target lesion(s), and the ‘on
demand’ treatment repetition, which reduces the likelihood of AE
occurrence with respect to a pre-determined fixed schedule (Ernst
et al, 1999; Jang et al, 2004).
Previous comparisons between DEB-TACE and cTACE con-
cerning patient survival demonstrated conflicting data. The
superiority of DEB-TACE is suggested by two retrospective studies
(Dhanasekaran et al, 2010; Song et al, 2012). However, the first one
dealt with small and differently sized groups enrolled in different
periods (Dhanasekaran et al, 2010). In the second study, the 18-
month survival rates were 88% in DEB-TACE patients and 61% in
cTACE patients, but the achievement of CR with cTACE was
surprisingly rare (as already mentioned above) and the survival
Table 2. Overall complete response by subgroups
cTACE
number/number
at risk (%)a
DEB-TACE
number/number
at risk (%) P
Effect
size
Child-Pugh class
A
1 month 45/77 (58.4%) 34/75 (45.3%) 0.144 0.291
3 months 41/72 (56.9%) 38/67 (56.7%) 40.999 0.005
6 months 39/67 (58.2%) 29/59 (49.2%) 0.371 0.201
B7–B8
1 month 7/10 (70.0%) 5/14 (35.7%) 0.214 0.791
3 months 6/9 (66.7%) 6/12 (50.0%) 0.660 0.382
6 months 4/7 (57.1%) 6/8 (75.0%) 0.608 0.447
Bilobar involvement
Absent
1 month 45/67 (67.2%) 36/72 (50.0%) 0.058 0.395
3 months 40/64 (62.5%) 37/63 (58.7%) 0.718 0.087
6 months 38/62 (61.3%) 28/52 (53.8%) 0.451 0.168
Present
1 month 7/20 (35.0%) 3/17 (17.6%) 0.288 0.508
3 months 7/17 (41.2%) 7/16 (43.8%) 40.999 0.058
6 months 5/12 (41.7%) 7/15 (46.7%) 40.999 0.112
ECOG
0
1 month 38/63 (60.3%) 25/67 (37.3%) 0.014 0.517
3 months 37/60 (61.7%) 29/58 (50.0%) 0.266 0.262
6 months 31/57 (54.4%) 24/50 (48.0%) 0.564 0.141
1
1 month 14/24 (58.3%) 14/22 (63.6%) 0.769 0.123
3 months 10/21 (47.6%) 6/15 (28.6%) 0.208 0.558
6 months 12/17 (29.4%) 11/17 (64.7%) 40.999 0.148
BCLC
Stage A
1 month 32/40 (80.0%) 20/41 (48.8%) 0.005 0.689
3 months 26/40 (65.0%) 21/36 (58.3%) 0.639 0.137
6 months 27/39 (69.2%) 16/31 (51.6%) 0.147 0.366
Stage B
1 month 6/23 (26.1%) 5/26 (19.2%) 0.734 0.164
3 months 11/20 (55.0%) 8/22 (36.4%) 0.352 0.380
6 months 4/18 (22.2%) 8/19 (42.1%) 0.295 0.436
Stage C
1 month 14/24 (58.3%) 14/22 (63.6%) 0.769 0.109
3 months 10/21 (47.6%) 15/21 (71.4%) 0.208 0.500
6 months 12/17 (70.6%) 11/17 (64.7%) 40.999 0.126
Abbreviations: BCLC¼Barcelona Clinic Liver Cancer; cTACE¼ conventional transarterial
chemoembolisation; DEB-TACE¼drug-eluting beads transarterial chemoembolisation;
ECOG¼Eastern Cooperative Oncology Group.
aOne patient in the cTACE group died before 1-month assessment.
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Figure 4. Patient survival after cTACE (triangle plot) and DEB-TACE
(square plot).
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analysis after the first year of follow-up was based on a very low
number of cases at risk (Song et al, 2012). Conversely, a small
randomised, single-centre study failed to demonstrate differences
between the two techniques in terms of TTP and tumour
recurrence and overall survival (Sacco et al, 2011). Finally,
statistically significant better overall survival after cTACE with
respect to DEB-TACE has emerged from another small retro-
spective study (Scartozzi et al, 2010).
The figures of 1- and 2-year overall survival (84.8% and 56.2%)
and median survival projection (29 months) of our patients are
within the wide range of values reported in the literature,
depending on the heterogeneity of the patients enrolled regarding
the aetiology of the liver disease, PS, Child-Pugh class, tumour
burden and stage, and prevalence of cases in which previous
treatment had failed to control cancer growth or HCC had
recurred (Llovet et al, 2002; Lo et al, 2002; Varela et al, 2007;
Doffoe¨l et al, 2008; Dhanasekaran et al, 2010; Sacco et al, 2011;
Burrel et al, 2012; Song et al, 2012; Takayasu et al, 2012).
The principal result of our study was that the type of TACE did
not affect 2-year survival, which was instead adversely conditioned
by PS 1, low serum albumin, and the presence of multiple tumours.
Considering the strong prognostic role of PS, a more favourable PS
scenario may explain the higher 2-year survival rates reported by
other studies (Burrel et al, 2012; Malagari et al, 2012). The
prognostic role of liver function has been already observed in
patients undergoing DEB-TACE, with a 2-year survival rate
of 88% in Child-Pugh class A and 75% in class B (Malagari et al,
2012). This suggests that the preservation of the extra-tumoural
liver is essential for achieving good results with TACE.
Therefore, between-arms equivalent liver toxicity was an important
determinant of our results regarding survival. Concerning
multinodularity, our study confirmed that multifocal hepatocarcino-
genesis could decrease the efficacy of TACE, regardless of the
technique utilised.
Eluting beads are innovative but costly medical devices, causing
an overcost of at least h600/treatment for DEB-TACE over cTACE,
offering equivalent clinical outcomes without any gain in hospital
stay, making it difficult to justify their systematic employment.
Limitations of the study. The first limitation may derive from the
enrolment interruption before reaching the planned sample size.
However, it can be pointed out that an accepted reason for
stopping a trial is its ‘futility’, suggested by interim analyses
indicating that it is highly unlikely that the study will show any
benefit from the experimental treatment (in our case DEB-TACE)
as compared with the control treatment (cTACE) if the trial is
continued (Casazza and Casella, 2012). Stopping trials for futility
makes it possible to save time and research funds for other issues.
Another possible limitation originates from the sample size,
which was calculated considering: (1) a 2-year survival rate of 40%
in the cTACE group which was a value in between those (31% and
63%) reported by the two randomised studies available at the time
we planned the trial (Llovet et al, 2002; Lo et al, 2002), and (2) a
20% superiority of DEB-TACE, an optimistic view suggested by the
theoretically superior advantages of the new procedure (Varela
et al, 2007).
The third limitation is associated with the ‘pragmatic design’ of
our trial, which allowed clinicians to utilise additional treatments at
the time of TACE failure (or after a successful downstaging). We
chose this approach not only for ethical reasons, but also to
compare the two TACE techniques in a setting mimicking what
actually happens in clinical practice. As a result, 26 out of 177
patients underwent complementary or sequential treatment.
However, the distribution of additional treatments did not differ
between the two TACE arms, and the great impact of liver
transplant on survival was limited by censoring patients at the time
of surgery. It is therefore likely that additional therapy had a
similar, if any, weight in the two TACE arms.
Finally, our study included BCLC C patients, in whom the use of
TACE may be debatable. However, this presence was due to the
fact that we did not consider this stage as a contraindication to
TACE, if the shift from B to C stage was only caused by PS-1
Table 3. Univariate and multivariate regression model on patient survival
Univariate Multivariate
HR (95% CI) P HR (95% CI) P
Primary therapeutic intervention
cTACE vs DC-Bead 0.985 (0.623–1.559) 0.949 — —
Clinical characteristics
Age (year) 1.024 (0.992–1.057) 0.144 — —
Male vs female 0.708 (0.419–1.194) 0.195 — —
Viral cirrhosis vs non-viral 1.535 (0.881–2.673) 0.130 — —
Alcohol consumption 0.453 (0.225–0.911) 0.026 0.553 (0.278–1.102) 0.092
Child-Pugh class B vs A class 1.889 (1.053–3.387) 0.033 1.109 (0.560–2.196) 0.766
ECOG 1 vs 0 1.635 (1.003–2.665) 0.049 1.904 (1.148–3.155) 0.013
Serum albumin (per g l1) 0.936 (0.899–0.974) 0.001 0.955 (0.915–0.997) 0.036
MELD score (per unit) 1.062 (0.961–1.173) 0.239 — —
Tumour burden
Multiple tumours vs single tumours 2.455 (1.488–4.049) 0.001 2.860 (1.692–4.833) 0.001
BCLC Stage C vs B vs Stage A 1.342 (1.020–1.766) 0.035 1.078 (0.599–1.939) 0.803
Bilobar involvement vs monolobar 1.360 (0.732–2.527) 0.330 — —
Largest tumour diameter (per cm) 1.002 (0.989–1.014) 0.805 — —
Segmental injection 1.075 (0.656–1.761) 0.775 — —
Abbreviations: BCLC¼Barcelona Clinic Liver Cancer; CI¼ confidence interval; cTACE¼ conventional transarterial chemoembolisation; DEB¼drug-eluting beads; ECOG¼Eastern
Cooperative Oncology Group; HR¼ hazard ratio; INR¼ international normalized ratio; MELD¼model for end-stage liver disease. Variables with a P-value of o0.10 at univariate analysis
were entered in multivariate Cox regression.
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which, in the ECOG definition, indicated patients ‘unable to carry
out a strenuous exercise but able to perform the usual activities of
normal life’. As a matter of fact, many centres do not consider PS 1
an excluding factor for intra-arterial treatments (Lammer et al,
2010; Malagari et al, 2012), and such a position has been recently
endorsed by the Italian guidelines for HCC managements (Bolondi
et al, 2013). Nevertheless, this point can be considered in
comparing our results with those of other studies using the BCLC
B stage and PS1 as thresholds for TACE treatment.
In conclusion, the present study failed to demonstrate a
superiority of DEB-TACE over cTACE in terms of efficacy,
safety and, more importantly, 2-year survival. The only benefit of
DEB-TACE was a lower incidence and intensity of post-
procedural abdominal pain. However, since this did not affect
the length of in-hospital stay and patient acceptance of
additional TACEs, this marginal advantage is offset, in our
opinion, by the higher cost of the new technique. Hence, the
routine use of DEB-TACE in clinical practice is debatable, unless
further studies can identify patient subgroups in which its use is
more beneficial for outcome.
OTHER MEMBERS OF THE PRECISION ITALIA STUDY
GROUP
Department of Digestive Disease and Internal Medicine,
S. Orsola-Malpighi Hospital, University of Bologna: Cristina
Mosconi, Alberta Cappelli, Maria Cristina Galaverni (Radiology
Table 4. Abdominal pain and adverse event related to TACE procedure within 30 days after procedure
All patients (n¼177) cTACE (n¼88) DEB-TACE (n¼89) P Effect size
Post-procedural pain 85 (48.0%) 63 (71.6%) 22 (24.7%) 0.001 1.124
Grade 1 47 (26.6%) 27 (30.7%) 20 (22.5%) 0.237 0.233
Grade 2 22 (12.4%) 20 (22.7%) 2 (2.2%) 0.001 1.416
Grade 3 16 (9.0%) 16 (18.2%) 0 (0.0%) 0.001 Nc
Fever 17 (9.6%) 10 (11.4%) 7 (7.9%) 0.457 0.224
Grade 1 6 (3.4%) 5 (5.7%) 1 (1.1%) 0.118 0.933
Grade 2 6 (3.4%) 4 (4.5%) 2 (2.2%) 0.444 0.408
Grade 3 5 (2.8%) 1 (1.1%) 4 (4.5%) 0.243 0.784
Pain 15 (8.5%) 11 (12.5%) 4 (4.5%) 0.064 0.612
Grade 1 5 (2.8%) 3 (3.4%) 2 (2.2%) 0.999 0.247
Grade 2 6 (3.4%) 5 (5.7%) 1 (1.1%) 0.118 0.933
Grade 3 4 (2.3%) 3 (3.4%) 1 (1.1%) 0.368 0.635
Fatigue 4 (2.3%) 4 (4.5%) 0 (0.0%) 0.059 Nc
Grade 1 1 (0.6%) 1 (1.1%) 0 (0.0%) 0.497 Nc
Grade 2 3 (1.7%) 3 (3.4%) 0 (0.0%) 0.121 Nc
Nausea/vomiting 5 (2.8%) 3 (3.4%) 2 (2.2%) 0.682 0.247
Grade 2 5 (2.8%) 3 (3.4%) 2 (2.2%)
Haematoma 4 (2.3%) 3 (3.4%) 1 (1.1%) 0.368 0.635
Grade 1 4 (2.3%) 3 (3.4%) 1 (1.1%)
Cholecystitis 3 (1.7%) 1 (1.1%) 2 (2.2%) 0.999 0.388
Grade 2 2 (1.1%) 1 (1.1%) 1 (1.1%) 0.999 0.000
Grade 3 1 (0.6%) 0 (0.0%) 1 (1.1%) 0.999 Nc
Necrosis (spleen infarction) 1 (0.6%) 0 (0.0%) 1 (1.1%) 0.999 Nc
Grade 1 1 (0.6%) 0 (0.0%) 1 (1.1%)
Infection 1 (0.6%) 1 (1.1%) 0 (0.0%) 0.497 Nc
Grade 5 1 (0.6%) 1 (1.1%) 0 (0.0%)
Allergic reaction 2 (1.1%) 1 (1.1%) 1 (1.1%) 0.999
Grade 1 2 (1.1%) 1 (1.1%) 1 (1.1%) 0.000
Increased ALTa 3 (1.7%) 3 (3.4%) 0 (0.0%) 0.121 Nc
Grade 1 2 (1.1%) 2 (2.3%) 0 (0.0%) 0.246 Nc
Grade 2 1 (0.6%) 1 (1.1%) 0 (0.0%) 0.497 Nc
Liver abscess 2 (1.1%) 1 (1.1%) 1 (1.1%) 0.999 0.000
Grade 2 2 (1.1%) 1 (1.1%) 1 (1.1%)
Liver function worseninga 6 (3.4%) 5 (5.7%) 1 (1.1%) 0.118 0.933
Other complications 7 (4.0%) 4 (4.5%) 3 (3.4%) 0.720 0.161
At least one severe AE 11 (6.2%) 5 (5.7%) 6 (6.7%) 0.999 0.095
Abbreviations: AE¼ adverse event; ALT¼ alanine aminotransferase; cTACE¼ conventional transarterial chemoembolisation; DEB-TACE¼drug-eluting beads transarterial chemoembolisation;
Nc¼ not computable due to zero events in one class.
aIncrease in Child-Pugh score of X2 points.
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Assistance to Liver Transplant patients).
Diagnostic and Interventional Radiology-Department of
Oncology Transplants and Advanced Technologies in Medicine,
University of Pisa: Claudio Vignali, Francesca Bianchi, Valentina
Vallini (Radiology Unit), Paola Carrai, Franco Filipponi (Hepatic
surgery and liver transplantation), Sara Moneta (Infectious diseases
– Campo di Marte Hospital, Pisa), Enrica Pea (Internal Medicine),
Stefano Giunta (Gastroenterology – Versilia hospital – Lucca),
Rodolfo Sacco, Angelo Ricchiuti, Giorgia di Fluri, (Gastroenterology
and Metabolic Diseases – Pisa University Hospital) Barbara Coco
(Hepatology, Pisa University Hospital).
Diagnostic Imaging Division-Department of Medical and
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of Turin: Denis Rossato, Cristina Vighetti, Giacomo Battisti,
Alessandro Rapellino (Radiology Unit); Patrizia Carucci, Loretta
Cosso, Mario Rizzetto (Gastroenterology and Hepatology); Stefano
Mirabella, Luisa Sturniolo, Giorgia Catalano, Mauro Salizzoni
(Liver Transplant Center, General Surgery).
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